NCT05980598 - TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions

Head and Neck Neoplasms

Interventions

DRUG

TransCon TLR7/8 Agonist

TLR7/8 agonist prodrug

DRUG

Pembrolizumab

A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding

DRUG

TransCon IL-2 β/γ

Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells

Trial Locations (65)

333

Ascendis Investigational Site, Taoyuan District

404

Ascendis Investigational Site, Taichung

1122

Ascendis Investigational Site, Budapest

4032

Ascendis Investigational Site, Debrecen

4600

Ascendis Investigational Site, Kutaisi

7624

Ascendis Investigational Site, Pécs

8900

Ascendis Investigational Site, Zalaegerszeg

9024

Ascendis Investigational Site, Győr

11794

Ascendis Investigational Site, New York

17475

Ascendis Investigational Site, Greifswald

20089

Ascendis Investigational Site, Rozzano

20133

Ascendis Investigational Site, Milan

20141

Ascendis Investigational Site, Milan

27003

Ascendis Investigational Site, Lugo

27100

Ascendis Investigational Site, Pavia

28027

Ascendis Investigational Site, Madrid

28040

Ascendis Investigational Site II, Madrid

Ascendis Investigational Site, Madrid

28050

Ascendis Investigational Site, Madrid

28100

Ascendis Investigational Site, Novara

29011

Ascendis Investigational Site, Málaga

29425

Ascendis Investigational Site, Charleston

30120

Ascendis Investigational Site, El Palmar

31008

Ascendis Investigational Site, Pamplona

37902

Ascendis Investigational Site, Knoxville

40202

Ascendis Investigational Site, Louisville

41125

Ascendis Investigational Site, Modena

43210

Ascendis Investigational Site, Columbus

44718

Ascendis Pharma Investigational Site, Canton

45219

Ascendis Investigational Site, Cincinnati

46009

Ascendis Investigational Site, Valencia

46014

Ascendis Investigational Site, Valencia

46026

Ascendis Investigational Site, Valencia

47014

Ascendis Investigational Site, Meldola

48201

Ascendis Investigational Site, Detroit

50009

Ascendis Investigational Site, Zaragoza

52242

Ascendis Investigational Site, Iowa City

55905

Ascendis Investigational Site, Rochester

60612

Ascendis Investigational Site, Chicago

62702

Ascendis Investigational Site, Springfield

68167

Ascendis Investigational Site, Mannheim

70456

Ascendis Investigational Site, Tainan City

77030

Ascendis Investigational Site, Houston

80131

Ascendis Investigational Site, Naples

80708

Ascendis Investigational Site, Kaohsiung City

83301

Ascendis Investigational Site, Kaohsiung City

89075

Ascendis Investigational Site, Ulm

90067

Ascendis Investigational Site, Los Angeles

91054

Ascendis Investigational Site, Erlangen

94158

Ascendis Investigational Site, San Francisco

02114

Ascendis Investigational Site, Boston

0114

Ascendis Investigational Site, Tbilisi

0144

Ascendis Investigational Site, Tbilisi

0159

Ascendis Investigational Site II, Tbilisi

Ascendis Investigational Site, Tbilisi

0186

Ascendis Investigational Site, Tbilisi

07747

Ascendis Investigational Site, Jena

04103

Ascendis Investigational Site, Leipzig

44-102

Ascendis Investigational Site, Gliwice

08-110

Ascendis Investigational Site, Siedlce

02-781

Ascendis Investigational Site, Warsaw

08003

Ascendis Investigational Site, Barcelona

08035

Ascendis Investigational Site, Barcelona

08908

Ascendis Investigational Site, L'Hospitalet de Llobregat

08221

Ascendis Investigational Site, Terrassa